Tertomotide

Drug Profile

Tertomotide

Alternative Names: GV1001; hTERT RNA vaccine - KAEL-GemVax; LucaVax; Telomerase peptide vaccine - KAEL-GemVax; TeloVac

Latest Information Update: 30 Nov 2016

Price : $50

At a glance

  • Originator Pharmexa
  • Developer Affitech A/S; Cancer Research UK; KAEL-GemVax; Lytix Biopharma; Norwegian Radium Hospital; Pharmexa
  • Class Cancer vaccines; Peptide fragments; Ribonucleoproteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pancreatic cancer
  • Phase II Benign prostatic hyperplasia; Non-small cell lung cancer
  • Phase I/II Malignant melanoma
  • Phase I Solid tumours
  • Discontinued Hepatocellular carcinoma

Most Recent Events

  • 01 Oct 2016 GemVax completes a phase-II clinical trial in Benign prostatic hyperplasia in South Korea (Intradermal) (NCT02855892)
  • 13 May 2015 Tertomotide is still in clinical development for Non-small cell lung cancer, Malignant melanoma and Solid tumours
  • 13 May 2015 Discontinued - Phase-II for Hepatocellular carcinoma in France, Spain, Germany (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top